Cancer immunotherapy: the beginning of the end of cancer?

Иммунотерапия рака: начало конца рака?
Eleftherios P. Diamandis, Sofia Farkona, Ivan M. Blasutig
2016-05-05

CTLA-4PD-1cancer immunotherapyimmune checkpoint blockadeoncolytic viruses
These are exciting times for cancer immunotherapy. After many years of disappointing results, the tide has finally changed and immunotherapy has become a clinically validated treatment for many cancers. Immunotherapeutic strategies include cancer vaccines, oncolytic viruses, adoptive transfer of ex vivo activated T and natural killer cells, and administration of antibodies or recombinant proteins that either costimulate cells or block the so-called immune checkpoint pathways. The recent success of several immunotherapeutic regimes, such as monoclonal antibody blocking of cytotoxic T lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD1), has boosted the development of this treatment modality, with the consequence that new therapeutic targets and schemes which combine various immunological agents are now being described at a breathtaking pace. In this review, we outline some of the main strategies in cancer immunotherapy (cancer vaccines, adoptive cellular immunotherapy, immune checkpoint blockade, and oncolytic viruses) and discuss the progress in the synergistic design of immune-targeting combination therapies.
1
Blocking immune checkpoints CTLA-4 and PD-1 has produced important clinical successes and accelerated development of cancer immunotherapies.
2
Cancer immunotherapy has become a clinically validated treatment for many cancers after years of disappointing results.
3
Major immunotherapeutic strategies include cancer vaccines, oncolytic viruses, adoptive transfer of activated T or natural killer cells, and immune-modulating antibodies or proteins.
4
Synergistic combinations of vaccines, cellular therapies, checkpoint blockade, and oncolytic viruses represent a major direction for advancing cancer treatment.
5
The field is rapidly identifying new therapeutic targets and designing combination regimens that integrate multiple immunological agents.

cancer immunotherapy

therapeutic strategies and synergistic combination designs, including cancer vaccines, adoptive cellular immunotherapy, immune checkpoint blockade, and oncolytic viruses

Publication Details
Publication Date
2016-05-05
Journal
Publisher
ISSN
Access Type
Author Information
Authors
Eleftherios P. Diamandis
Sofia Farkona
Ivan M. Blasutig
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%